PMID- 19453200
OWN - NLM
STAT- MEDLINE
DCOM- 20090812
LR  - 20211020
IS  - 1172-7047 (Print)
IS  - 1172-7047 (Linking)
VI  - 23
IP  - 5
DP  - 2009
TI  - Neutralizing antibodies to interferon-beta and other immunological treatments for 
      multiple sclerosis: prevalence and impact on outcomes.
PG  - 379-96
LID - 10.2165/00023210-200923050-00003 [doi]
AB  - Biopharmaceuticals can induce antibodies, which interact with and neutralize the 
      therapeutic effect of such drugs and are therefore termed neutralizing antibodies 
      (NAbs). In the treatment of multiple sclerosis, NAbs against interferon 
      (IFN)-beta and natalizumab have been recognized. The prevalence of NAbs against 
      different IFNbeta preparations varies widely, mainly depending on the product but 
      also on other factors such as amino acid sequence variations, glycosylation, 
      formulation, route and frequency of application, dose, duration of treatment and 
      patient characteristics (human leukocyte antigen [HLA] status). IFNbeta-1a given 
      intramuscularly induces significantly less NAbs than any other IFNbeta 
      formulation. The longitudinal development of NAbs also differs between IFNbeta 
      preparations, with higher reversion rates in IFNbeta-1b-treated compared with 
      IFNbeta-1a-treated patients. The negative effect of NAbs on various outcome 
      measures is very consistent across many studies, specifically when observation 
      periods are longer than 2 years. NAbs against natalizumab occur less frequently 
      (6%) and, like NAbs against IFNbeta, they are associated with a loss of clinical 
      and radiological efficacy of the drug.
FAU - Deisenhammer, Florian
AU  - Deisenhammer F
AD  - Department of Neurology, Innsbruck Medical University, Anichstrasse 35, Innsbruck 
      6020, Austria. florian.deisenhammer@i-med.ac.at
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - CNS Drugs
JT  - CNS drugs
JID - 9431220
RN  - 0 (Antibodies)
RN  - 0 (Immunologic Factors)
RN  - 77238-31-4 (Interferon-beta)
SB  - IM
MH  - Antibodies/*therapeutic use
MH  - Humans
MH  - Immunologic Factors/*therapeutic use
MH  - Interferon-beta/*immunology
MH  - Multiple Sclerosis/*drug therapy/epidemiology/*immunology
MH  - Treatment Outcome
RF  - 97
EDAT- 2009/05/21 09:00
MHDA- 2009/08/13 09:00
CRDT- 2009/05/21 09:00
PHST- 2009/05/21 09:00 [entrez]
PHST- 2009/05/21 09:00 [pubmed]
PHST- 2009/08/13 09:00 [medline]
AID - 3 [pii]
AID - 10.2165/00023210-200923050-00003 [doi]
PST - ppublish
SO  - CNS Drugs. 2009;23(5):379-96. doi: 10.2165/00023210-200923050-00003.